U.S. markets close in 2 hours 21 minutes
  • S&P 500

    4,134.23
    +6.24 (+0.15%)
     
  • Dow 30

    33,594.15
    -151.25 (-0.45%)
     
  • Nasdaq

    13,955.18
    +105.18 (+0.76%)
     
  • Russell 2000

    2,212.44
    -21.34 (-0.96%)
     
  • Crude Oil

    60.20
    +0.50 (+0.84%)
     
  • Gold

    1,747.40
    +14.70 (+0.85%)
     
  • Silver

    25.41
    +0.54 (+2.18%)
     
  • EUR/USD

    1.1946
    +0.0028 (+0.24%)
     
  • 10-Yr Bond

    1.6290
    -0.0460 (-2.75%)
     
  • GBP/USD

    1.3748
    +0.0006 (+0.04%)
     
  • USD/JPY

    109.0630
    -0.3130 (-0.29%)
     
  • BTC-USD

    63,249.79
    +3,091.93 (+5.14%)
     
  • CMC Crypto 200

    1,354.67
    +60.68 (+4.69%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials Fund, Global X Junior MLP, PowerShares S&P SmallCap Information Technology Portfolio, iShares Morningstar Small-Cap Growth and Guggenheim S&P SmallCap 600 Pure Growth

Zacks Equity Research

For Immediate Release

Chicago, IL – June 07, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include BioShares Biotechnology Clinical Trials Fund (BBC), Global X Junior MLP ETF (MLPJ), PowerShares S&P SmallCap Information Technology Portfolio (PSCT), iShares Morningstar Small-Cap Growth ETF (JKK) and Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Market on the Rise: 5 Small-Cap ETFs Leading the Way

The U.S. stock market has shown some strength in recent weeks, especially following the Fed’s hawkish comments and a spate of positive economic indicators. While the S&P 500 touched new 2016 highs, small caps as represented by the Russell 2000 are leading the current rally. Though the regained momentum in the U.S. economy spread a strong air of optimism in the small cap space, Brexit fears, the Fed policy, a strong dollar and slow growth in many corners of the world continue to keep many investors away from large cap stocks.

This is especially true given that the ultra-popular small cap ETF has gained nearly 3.7% over the past one-month compared to a gain of about 2.2% for the SPDR 500. The economy was off to a strong start in the second quarter after stalling in the first as inflation picked up, manufacturing stabilized and industrial production started rising. The housing market is showing signs of a spring rebound given that new home construction and building permits rebounded in April (read: Play US Recovery with These Small-Cap Blend ETFs ).

In addition, retail sales jumped 1.3% in April, representing the largest gain since March 2015, buoyed by online shopping. Consumer confidence also bounced back to its strongest level in nearly a year in May, with the preliminary University of Michigan sentiment index reading 95.8, up from 89 in April. All these suggest that the world’s largest economy has regained momentum, benefiting small caps the most.

This is because these pint-sized stocks are closely tied to the U.S. economy and generate most of their revenues from the domestic market, potentially freeing them from the clutches of a global malaise. Additionally, these stocks generally outperform when the American economy is leading the way. Further, since these companies are small, they are poised to grow more than their already tapped out large cap counterparts.

Below, we have highlighted five small cap ETFs that are easily crushing the overall market over the past one month (see: all the Small Caps ETFs here).

BioShares Biotechnology Clinical Trials Fund (BBC)

This ETF has a novel approach to biotechnology investing as it provides exposure to companies that have a primary product in Phase I, II, or III of FDA trials by tracking the LifeSci Biotechnology Clinical Trials Index. Holding 90 small cap stocks in its basket, the fund is widely spread out as each firm holds no more than 2.7% share. The fund has accumulated $27.6 million in its asset base and charges a higher fee of 85 bps per year. It trades in a light volume of 13,000 shares a day and gained 9.5% over the past one-month period. The fund has a Zacks ETF Rank of 3 or ‘Hold’ rating.

Global X Junior MLP ETF (MLPJ)

This product targets the small cap MLP segment of the energy market. It tracks the performance of the Solactive Junior MLP Composite Index and holds 31 stocks with moderate concentration across components as each holds less than 8.8% of assets. It charges 0.75% in fees per year and trades in paltry average daily volume of less than 8,000 shares. With AUM of 6.4 million, MLPJ gained 7.8% over the past one month (read: MLP ETFs--Time to Invest on Oil Rebound or Too Risky? ).

PowerShares S&P SmallCap Information Technology Portfolio (PSCT)

This fund provides exposure to the small cap technology segment by tracking the S&P SmallCap 600 Capped Information Technology Index. It has amassed $379 million in its asset base and trades in average daily volume of about 37,000 shares. The ETF charges 29 bps in fees per year from investors. Holding 97 securities in its basket, the product is well spread across securities with none holding more than 3.36% share. From an industry look, about one-fourth of the portfolio is allocated toward electronic equipment, followed by semiconductors (22.2%) and software (8.5%). The product added over 4.6% in the same time frame and has a Zacks ETF Rank of 2 or ‘Buy’ rating (read: Forget Big Tech, Focus on These ETFs Instead ).

iShares Morningstar Small-Cap Growth ETF (JKK)

This ETF offers exposure to small cap companies whose earnings are expected to grow at an above-average rate relative to the market. It follows the Morningstar Small Growth Index and holds 270 securities in its basket with none accounting for more than 1.44% of assets. Information technology accounts for the largest share of 27.3% while health care, financials, consumer discretionary, and industrials round off the top five spots. The ETF charges 30 bps in annual fees and trades in a light volume of about 3,000 shares a day. It has amassed $115.5 million in its asset base and returned about 4.4% in the same period. JKK has a Zacks ETF Rank of 3.

Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG)

This fund also targets the small cap growth segment of the broader U.S. market. It tracks the S&P SmallCap 600 Pure Growth Index, charging investors 35 bps in annual fees. Holding 142 securities in its basket, it is well spread out across components with each holding less than 2% share. Health care and financials take the top two spots with 27.2% and 21.8%, share, respectively, while industrials, information technology and consumer discretionary round off the top five with a double-digit allocation each. The fund has amassed $174.3 million in its asset base while trades in volume of about 23,000 shares a day on average. The product gained 7.2% over the past month and has a Zacks ETF Rank of 3.

Bottom Line

Small caps have lately been gaining, and should remain lucrative bets for investors for as long as global volatility persists and the U.S. economy shows improvement.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BIOSH-BIO CLNCL (BBC): ETF Research Reports
 
GLBL-X JR MLP (MLPJ): ETF Research Reports
 
PWRSH-SP SC IT (PSCT): ETF Research Reports
 
ISHARS-MO SC GR (JKK): ETF Research Reports
 
GUGG-SP 600 PG (RZG): ETF Research Reports
 
To read this article on Zacks.com click here.